Mitsubishi UFJ Asset Management Co. Ltd. Has $18.69 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Key Points

• Mitsubishi UFJ Asset Management Co. Ltd. has increased its stake in Moderna, Inc. by 28.8%, owning approximately 659,250 shares valued at $18.69 million as of the latest filing.
• Multiple hedge funds have also boosted their positions in Moderna, with 75.33% of the stock now owned by institutional investors.
• Moderna's recent earnings report indicated a loss per share of ($2.13), which was better than analysts' expectations, but revenue decreased by 41.1% year-over-year.

Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 28.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 659,250 shares of the company's stock after purchasing an additional 147,267 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.17% of Moderna worth $18,690,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRNA. Russell Investments Group Ltd. boosted its stake in shares of Moderna by 81.3% during the 4th quarter. Russell Investments Group Ltd. now owns 170,243 shares of the company's stock worth $7,019,000 after acquiring an additional 76,350 shares in the last quarter. Advisory Services Network LLC boosted its stake in shares of Moderna by 543.1% during the 4th quarter. Advisory Services Network LLC now owns 19,603 shares of the company's stock worth $815,000 after acquiring an additional 16,555 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Moderna during the 4th quarter worth about $8,493,000. Treasurer of the State of North Carolina boosted its stake in shares of Moderna by 3.8% during the 4th quarter. Treasurer of the State of North Carolina now owns 206,884 shares of the company's stock worth $8,602,000 after acquiring an additional 7,490 shares in the last quarter. Finally, Townsquare Capital LLC boosted its stake in shares of Moderna by 14.2% during the 4th quarter. Townsquare Capital LLC now owns 6,040 shares of the company's stock worth $251,000 after acquiring an additional 752 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MRNA. Bank of America decreased their price target on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research note on Tuesday, July 22nd. Citigroup assumed coverage on Moderna in a research note on Friday, August 1st. They set a "neutral" rating and a $40.00 target price for the company. UBS Group decreased their target price on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. JPMorgan Chase & Co. set a $26.00 target price on Moderna in a research note on Friday, August 1st. Finally, Cowen assumed coverage on Moderna in a research note on Sunday, July 13th. They set a "hold" rating for the company. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $43.59.

Moderna Price Performance

Shares of MRNA traded up $1.23 during mid-day trading on Wednesday, reaching $26.89. The company had a trading volume of 8,647,828 shares, compared to its average volume of 10,839,467. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $91.99. The company's 50-day moving average is $29.18 and its 200-day moving average is $29.73. The company has a market capitalization of $10.46 billion, a P/E ratio of -3.57 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%. The business had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. During the same period in the prior year, the firm posted ($3.33) EPS. Moderna's quarterly revenue was down 41.1% compared to the same quarter last year. As a group, equities analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.